ATE496631T1 - Melanomtherapie - Google Patents

Melanomtherapie

Info

Publication number
ATE496631T1
ATE496631T1 AT08020311T AT08020311T ATE496631T1 AT E496631 T1 ATE496631 T1 AT E496631T1 AT 08020311 T AT08020311 T AT 08020311T AT 08020311 T AT08020311 T AT 08020311T AT E496631 T1 ATE496631 T1 AT E496631T1
Authority
AT
Austria
Prior art keywords
melanoma therapy
melanoma
therapy
Prior art date
Application number
AT08020311T
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE496631T1 publication Critical patent/ATE496631T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT08020311T 1999-04-08 2000-04-06 Melanomtherapie ATE496631T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
ATE496631T1 true ATE496631T1 (de) 2011-02-15

Family

ID=23106795

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08020311T ATE496631T1 (de) 1999-04-08 2000-04-06 Melanomtherapie
AT05002951T ATE419001T1 (de) 1999-04-08 2000-04-06 Melanoma therapie
AT00107101T ATE296639T1 (de) 1999-04-08 2000-04-06 Melanoma therapie

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT05002951T ATE419001T1 (de) 1999-04-08 2000-04-06 Melanoma therapie
AT00107101T ATE296639T1 (de) 1999-04-08 2000-04-06 Melanoma therapie

Country Status (22)

Country Link
EP (3) EP1043026B1 (de)
JP (1) JP2000319195A (de)
CN (1) CN1390132A (de)
AR (1) AR023398A1 (de)
AT (3) ATE496631T1 (de)
AU (1) AU771569B2 (de)
BR (1) BR0009646A (de)
CA (1) CA2303992A1 (de)
CO (1) CO5170404A1 (de)
CY (1) CY1108922T1 (de)
DE (3) DE60041290D1 (de)
DK (2) DK1043026T3 (de)
ES (2) ES2319776T3 (de)
HK (2) HK1032349A1 (de)
HU (1) HU230057B1 (de)
MY (1) MY126763A (de)
NO (1) NO328111B1 (de)
PE (1) PE20010027A1 (de)
PT (2) PT1535622E (de)
TW (1) TWI292320B (de)
WO (1) WO2000061175A2 (de)
ZA (1) ZA200108173B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
AR023398A1 (es) 2002-09-04
BR0009646A (pt) 2002-02-05
CA2303992A1 (en) 2000-10-08
EP1043026A2 (de) 2000-10-11
EP2025344A1 (de) 2009-02-18
EP2025344B1 (de) 2011-01-26
EP1535622A1 (de) 2005-06-01
CN1390132A (zh) 2003-01-08
AU771569B2 (en) 2004-03-25
AU4204600A (en) 2000-11-14
DK1043026T3 (da) 2005-07-04
DK1535622T3 (da) 2009-04-20
CO5170404A1 (es) 2002-06-27
DE60020444T2 (de) 2006-05-04
PE20010027A1 (es) 2001-02-05
DE60045591D1 (de) 2011-03-10
JP2000319195A (ja) 2000-11-21
ES2239954T3 (es) 2005-10-16
NO20014852D0 (no) 2001-10-05
HU230057B1 (hu) 2015-06-29
DE60041290D1 (de) 2009-02-12
PT1535622E (pt) 2009-03-19
ES2319776T3 (es) 2009-05-12
ATE296639T1 (de) 2005-06-15
HK1075416A1 (en) 2005-12-16
HUP0200775A3 (en) 2002-09-30
EP1535622B1 (de) 2008-12-31
EP1043026A3 (de) 2000-12-20
MY126763A (en) 2006-10-31
ATE419001T1 (de) 2009-01-15
DE60020444D1 (de) 2005-07-07
WO2000061175A2 (en) 2000-10-19
ZA200108173B (en) 2003-01-06
TWI292320B (en) 2008-01-11
EP1043026B1 (de) 2005-06-01
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
PT1043026E (pt) 2005-09-30
WO2000061175A3 (en) 2001-02-01
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
HK1032349A1 (en) 2001-07-20

Similar Documents

Publication Publication Date Title
DK1637127T3 (da) Terapeutisk mikroskum
DE69924365D1 (de) Massagegerät
DE122007000064I1 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE60017816D1 (de) Herzschrittmacher
DE60040745D1 (de) Viertorhybrid
DE60016600D1 (de) Herzschrittmacher
DE59911113D1 (de) Herzschrittmacher
DE50015795D1 (de) Sektionaltor
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE69916133D1 (de) Elektro-neuro-adaptiver stimulator
DE60013608D1 (de) Herzschrittmacher
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE60016452D1 (de) Herzschrittmacher
ATE269311T1 (de) Benzoylpyridazine
ATA121799A (de) Ausbeulgerät
DE60045591D1 (de) Melanomtherapie
FI990832A0 (fi) Puuntyöstöyksikkö
ATA107599A (de) Heizwasserbereiter
DE10085167T1 (de) Gangumschalteinrichtung
ATA203199A (de) Ablauf

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties